periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible